2 Desember 2021
Avaiable online at www.jurnal-pharmaconmw.com/jmpi
p-ISSN : 2442-6032
e-ISSN : 2598-9979
ABSTRAK
Diabetes melitus (DM) adalah penyakit metabolik cinamic acid, sitagliptin, dan curcumin dalam bentuk
akibat gangguan aktivitas atau sekresi insulin, dengan tunggal ataupun kombinasi. Sediaan SNEDDS tersebut
angka kejadian dan morbiditas yang terus meningkat. diformulasi menggunakan minyak, surfaktan, dan
Sebagian agen antidiabetik oral diketahui memiliki kosurfaktan terpilih. Surfaktan yang banyak digunakan
kelarutan yang rendah dalam air, sehingga perlu adalah kelompok tween dan cremophor sedangkan
dilakukan modifikasi untuk meningkatkan kosurfaktan yang banyak digunakan adalah PEG400
efektifitasnya. Penelitian ini bertujuan untuk mengkaji dan transcutol. Pengembangan sediaan SNEDDS
pengembangan sediaan self nanoemulsifying drug terbukti secara signifikan dapat meningkatkan disolusi
delivery system (SNEDDS) mengandung agen agen antidiabetik oral dan juga meningkatkan
antidiabetik oral dan mengkaji pengaruhnya terhadap bioavailabilitasnya yang ditandai dengan peningkatan
disolusi, bioavailabilitas, dan efek farmakologinya. nilai AUC dan Cmax. Pengembangan SNEDDS juga
Penelitian dilakukan dengan berbasis systematic terbukti mampu menyebabkan penurunan kadar
literature review dengan mengkaji jurnal dari berbagai glukosa darah yang lebih baik dibandingkan dengan
database bereputasi yang memenuhi kriteria inklusi bentuk suspensi atau sediaan pasaran. Dari hasil kajian
dan eksklusi yang sudah ditetapkan. Berdasarkan hasil dapat disimpulkan jika SNEDDS sesuai digunakan
kajian diketahui bahwa SNEDDS sudah diaplikasikan untuk penghantaran agen antidiabetik oral terutama
untuk berbagai senyawa antidiabetik oral seperti yang memiliki kelarutan rendah dalam air
dapagliflozin, glibenclamid, gliclazid, glimepirid, Kata Kunci : diabetes melitus, antidiabetika oral, BCS
tolbutamid, repaglinid, polypeptide-k, exendin-4, trans- kelas 2, SNEDDS
ABSTRACT
Diabetes mellitus (DM) is a metabolic disease due to The SNEDDS were prepared using selected oils,
impaired insulin activity or secretion, with a very high surfactants, and cosurfactants. The most widely used
incidence and morbidity worldwide. Some oral surfactants are tween and cremophor, while PEG400
antidiabetic agents have low water solubility, so delivery and transcutol are commonly used as co-surfactants.
system modifications need to increase their The development of SNEDDS significantly increases the
effectiveness. This study aims to examine the dissolution of oral antidiabetic agents and their
development of a self nano emulsifying drug delivery bioavailability, which is indicated by an increase in
system (SNEDDS) containing an oral antidiabetic agent blood AUC and Cmax. The SNEDDS increase the
and to examine its effect on dissolution, bioavailability, reduction of blood glucose levels (BGL) compared to
and pharmacological activity. This study is based on a suspension dosage form or marketed products. It can be
systematic literature review by reviewing journals from concluded that SNEDDS is appropriate for delivering
various reputable databases that meet the inclusion and oral antidiabetic agents, especially those with low water
exclusion criteria. The study shows that SNEDDS have solubility.
been applied to many oral antidiabetic agents such as Keywords : Diabetes mellitus, oral antidiabetic agent,
dapagliflozin, glibenclamide, gliclazide, glimepiride, BCS class 2, SNEDD
tolbutamide, repaglinide, polypeptide-k, exendin-4,
trans-cinnamic acid, sitagliptin, and curcumin in single
or in combination form.
delivery systems: An update Garg, V., Kaur, J., Singh, C., Kaur,
of the biopharmaceutical B., Kumar, B., Narang, R., &
aspects. In Expert Opinion Singh, S. K. (2017).
on Drug Delivery. “polypeptide-k” as
https://doi.org/10.1517/1742 phytoinsulin: How much and
5247.2015.999038 how far. In International
Date, A. A., Desai, N., Dixit, R., & Journal of Green Pharmacy
Nagarsenker, M. (2010). (Vol. 11, Issue 2).
Self-nanoemulsifying drug Garg, V., Kaur, P., Gulati, M.,
delivery systems: Singh, S. K., Kumar, B.,
Formulation insights, Pandey, N. K., Yadav, A. K.,
applications and advances. Kumar, R., Kuppusamy, G.,
In Nanomedicine (Vol. 5, De, A., Puttappa, N., &
Issue 10). Wadhwa, S. (2019).
https://doi.org/10.2217/nnm Coadministration of
.10.126 Polypeptide-k and Curcumin
Desai, N. S., & Nagarsenker, M. S. Through Solid Self-
(2013). Design and Nanoemulsifying Drug
evaluation of self- Delivery System for Better
nanoemulsifying pellets of Therapeutic Effect Against
repaglinide. AAPS Diabetes Mellitus:
PharmSciTech, 14(3). Formulation, Optimization,
https://doi.org/10.1208/s12 Biopharmaceutical
249-013-9990-9 Characterization, and
Elgart, A., Cherniakov, I., Pharmacodynamic
Aldouby, Y., Domb, A. J., & Assessment. Assay and Drug
Hoffman, A. (2013). Development Technologies,
Improved oral bioavailability 17(4).
of BCS class 2 compounds by https://doi.org/10.1089/adt.
self nano-emulsifying drug 2018.902
delivery systems (SNEDDS): Garg, V., Kaur, P., Singh, S. K.,
The underlying mechanisms Kumar, B., Bawa, P., Gulati,
for amiodarone and talinolol. M., & Yadav, A. K. (2017).
Pharmaceutical Research, Solid self-nanoemulsifying
30(12). drug delivery systems for
https://doi.org/10.1007/s110 oral delivery of polypeptide-
95-013-1063-y k: Formulation,
Galicia-Garcia, U., Benito- optimization, in-vitro and in-
Vicente, A., Jebari, S., vivo antidiabetic evaluation.
Larrea-Sebal, A., Siddiqi, H., European Journal of
Uribe, K. B., Ostolaza, H., & Pharmaceutical Sciences,
Martín, C. (2020). 109.
Pathophysiology of type 2 https://doi.org/10.1016/j.ejp
diabetes mellitus. In s.2017.08.022
International Journal of Johnson, K. M. S., & Schurr, K.
Molecular Sciences (Vol. 21, (2011). Sitagliptin: A DPP-4
Issue 17). inhibitor for the treatment of
https://doi.org/10.3390/ijm type 2 diabetes mellitus. In
s21176275 Clinical Medicine Insights: